МЕХАНИЗМЫ СОПРОТИВЛЕНИЯ ОПУХОЛЕЙ БЛОКАДЕ ИММУННЫХ СВЕРОЧНЫХ ТОЧЕК (11-27)

Список литературы: 1. Chowell D. et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy // Science -2018. -№ 359. – с. 582 2. Fessler J. et al. Exploring the emerging role of the microbiome in cancer immunotherapy // J. Immunother. Cancer -2019. -№ 7. – с. 108 3. Rizvi N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non- small cell lung cancer // Science -2015. -№ 348. – с. 124 4. Snyder A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma // N. Engl. J. Med. -2014. -№ 371. – с. 2189 5. van Rooij N. et al. // Tumor exome analysis reveals neoantigen- specific T- cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. - 2013. -№ 31. – с. e439 6. Tran E. et al. Cancer immunotherapy based on mutation- specific CD4+ T cells in a patient with epithelial cancer // Science -2014. -№ 344. – с. 641 7. Ott P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma // Nature -2017. -№ 547. – с. 217 8. Dighe A. S. et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors // Immunity - 1994. №1, – с. 447 9. Kaplan D. H. et al. Demonstration of an interferon gamma- dependent tumor surveillance system in immunocompetent mice // Proc. Natl Acad. Sci. USA -1998. -№ 95. – с. 7556 10. Manguso R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target // Nature -2017. -№ 547. – с. 413 11. Patel S. J. et al. Identification of essential genes for cancer immunotherapy // Nature -2017. -№ 548. – с. 537 12. Pan D. et al. A major chromatin regulator determines resistance of tumor cells to T cell- mediated killing // Science -2018. -№ 359. – с. 770 13. Zaretsky J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma // N. Engl. J. Med. -2016. -№ 375. – с. 819 14. Gao J. et al. Loss of IFN- γ pathway genes in tumor cells as a mechanism of resistance to anti- CTLA-4 therapy // Cell -2016. -№ 167. – с. 397 15. Wilson E. B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection // Science -2013. -№ 340. – с. 202 16. Benci J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade // Cell -2016. -№ 167. – с. 1540 17. Bach E. A. et al. The IFN gamma receptor: a paradigm for cytokine receptor signaling // Annu. Rev. Immunol. -1997. -№ 15. – с. 563 18. Sucker A. et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cellresistant melanoma lesions // Nat. commun. -2017. -№ 8. – с. 15440 19. Shankaran V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity // Nature -2001. -№ 410. – с. 1107 20. Restifo N. P. et al. Identification of human cancers deficient in antigen processing // J. Exp. Med. -1993. -№ 177. – с. 265 21. Restifo N. P. et al. Loss of functional beta 2microglobulin in metastatic melanomas from five patients receiving immunotherapy // J. Natl. Cancer Inst. -1996. -№ 88. – с. 100 22. Sucker A. et al. Genetic evolution of T-cell resistance in the course of melanoma progression // Clin. Cancer Res. -2014. -№ 20. – с. 6593 23. McGranahan N. et al. Allele- specific HLA loss and immune escape in lung cancer evolution // Cell -2017. -№ 171. – с. 1259 24. Grasso C. S. et al. Genetic mechanisms of immune evasion in colorectal cancer // Cancer Discov. -2018. -№ 8. – с. 730 25. Huang L. et al. The RNA- binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA- A expression // Clin. Cancer Res. -2018. -№ 24. – с. 3366 26. Yaguchi T. et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells // J. Immunol. -2012. -№ 189. – с. 2110 27. Zhao F. et al. Paracrine Wnt5a- β-catenin signaling triggers a metabolic program that drives dendritic cell tolerization // Immunity -2018. -№ 48. – с. 147 28. Jimenez-Sanchez A. et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient // Cell -2017. -№ 170. – с. 927 29. Sridharan V. et al. Immune profiling of adenoid cystic carcinoma: PD- L2 expression and associations with tumor- infiltrating lymphocytes // Cancer Immunol. Res. -2016. -№ 4. – с. 679 30. Seiwert T. Y. et al. Integrative and comparative genomic analysis of HPV- positive and HPV- negative head and neck squamous cell carcinomas // Clin. Cancer Res. -2015. -№ 21. – с. 632 31. Sweis R. F. et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer // Cancer Immunol. Res. - 2016. -№ 4. – с. 563 32. Abril- Rodriguez G. T. et al. PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy [abstract O39, электронный ресурс]. – 2018. Режим доступа: URL: https://sitc.sitcancer.org/2018/abstracts/titles/?category =Mechanisms+of+Resistance+to+Immunotherapy 33. Hunter T. et al. Cyclins and cancer // Cell - 1991. -№ 66. – с. 1071 34. Deng J. et al. CDK4/6 inhibition augments antitumor immunity by enhancing T- cell activation // Cancer Discov. -2018. -№ 8. – с. 216 35. Jerby-Arnon L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade // Cell -2018. -№ 175. – с. 984 36. Sumimoto H. et al. The BRAF- MAPK signaling pathway is essential for cancer- immune evasion in human melanoma cells // J. Exp. Med. - 2006. -№ 203. – с. 1651 37. Boni A. et al. Selective BRAFV600E inhibition enhances T- cell recognition of melanoma without affecting lymphocyte function // Cancer Res. 2010. -№ 70. – с. 5213 38. Frederick D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma // Clin. Cancer Res. -2013. -№ 19. – с. 1225 39. Acquavella N. et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest // Cancer Immunol. Res. -2015. -№ 3. – с. 37 40. Hugo W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma // Cell -2016. -№ 165. – с. 35 41. Ebert P. J. R. et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade // Immunity -2016. - № 44. – с. 609 42. Hu-Lieskovan S. et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma // Sci. Transl. Med. -2015. -№ 7. – с. 279ra41 43. Ribas A. et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma // Nat. Med. -2019. -№ 25. – с. 936 44. Ascierto P. A. et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF- mutant melanoma // Nat. Med. -2019. -№ 25. – с. 941 45. Sullivan R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF- mutated melanoma patients // Nat. Med. -2019. -№ 25. – с. 929 46. Li J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer // Science -1997. -№ 275. – с. 1943 47. Peng W. et al. Loss of PTEN promotes resistance to T cell- mediated immunotherapy // Cancer Discov. -2016. -№ 6. – с. 202 48. George S. et al. Loss of PTEN is associated with resistance to anti- PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma // Immunity -2017. -№ 46. – с. 197 49. Li S. et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity // Nat. Immunol. -2016. -№ 17. – с. 241 50. Kaneda M. M. et al. PI3Kgamma is a molecular switch that controls immune suppression // Nature -2016. -№ 539. – с. 437 51. Mehta A. et al. Immunotherapy resistance by inflammation- induced dedifferentiation // Cancer Discov. -2018. -№ 8. – с. 935 52. Miao Y. et al. Adaptive immune resistance emerges from tumor- initiating stem cells // Cell -2019. -№ 177. – с. 1172 53. Castagnoli L. et al. WNT signaling modulates PD- L1 expression in the stem cell compartment of triplenegative breast cancer // Oncogene -2019. -№ 38. – с. 4047 54. Paczulla A. M. et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion // Nature -2019. -№ 572. – с. 254 55. Zhan T. et al. Wnt signaling in cancer // Oncogene -2017. -№ 36. – с. 1461 56. Menshawy A. et al. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta- analysis of randomized- controlled trials // Melanoma Res. -2018. -№ 28. – с. 371 57. Dudley M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes // Science -2002. -№ 298. – с. 850 58. Zeng D. Q. et al. Prognostic and predictive value of tumor- infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer // Oncotarget -2016. -№ 7. – с. 13765 59. Galon J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome // Science -2006. -№ 313. – с. 1960 60. Tumeh P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance // Nature -2014. -№ 515. – с. 568 61. Le D. T. et al. PD-1 blockade in tumors with mismatch repair deficiency // N. Engl. J. Med. -2015. - № 372. – с. 2509 62. Mariathasan S. et al. TGFβ attenuates tumour response to PD- L1 blockade by contributing to exclusion of T cells // Nature -2018. -№ 554. – с. 544 63. Riaz N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab // Cell -2017. -№ 171. – с. 934 64. Yost K. E. et al. Clonal replacement of tumor- specific T cells following PD-1 blockade // Nat. Med. -2019. -№ 25. – с. 1251 65. Topalian S. L. et al. Safety, activity, and immune correlates of anti- PD-1 antibody in cancer // N. Engl. J. Med. -2012. -№ 366. – с. 2443 66. Garon E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer // N. Engl. J. Med. -2015. -№ 372. – с. 2018 67. Wolchok J. D. et al. Nivolumab plus ipilimumab in advanced melanoma // N. Engl. J. Med. -2013. -№ 369. – с. 122 68. Robert C. et al. Nivolumab in previously untreated melanoma without BRAF mutation // N. Engl. J. Med. -2015. -№ 372. – с. 320 69. Forde P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer // N. Engl. J. Med. - 2018. -№ 378. – с. 1976 70. Chen G. et al. Exosomal PD- L1 contributes to immunosuppression and is associated with anti- PD- 1 response // Nature -2018. -№ 560. – с. 382 71. Ribas A. et al. What does PD- L1 positive or negative mean? // J. Exp. Med. -2016. -№ 213. – с. 2835 72. Newman A. M. et al. Robust enumeration of cell subsets from tissue expression profiles // Nat. Methods -2015. -№ 12. – с. 453 73. Becht E. et al. Estimating the population abundance of tissue- infiltrating immune and stromal cell populations using gene expression // Genome Biol. -2016. -№ 17. – с. 218 74. Rooney M. S. et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity // Cell -2015. -№ 160. – с. 48 75. Sade-Feldman M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma // Cell -2018. -№ 175. – с. 998 76. Nishino M. et al. Monitoring immune- checkpoint blockade: response evaluation and biomarker development // Nat. Rev. Clin. Oncol. -2017. -№ 14. – с. 655 77. McGranahan N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade // Science -2016. -№ 351. – с. 1463 78. Vitiello A. et al. Neoantigen prediction and the need for validation // Nat. Biotechnol. -2017. -№ 35. – с. 815 79. Wei S. C. et al. Fundamental mechanisms of immune checkpoint blockade therapy // Cancer Discov. -2018. -№ 8. – с. 1069 80. Gardner A. et al. Dendritic cells and cancer immunity // Trends Immunol. -2016. -№ 37. – с. 855 81. Redelman-Sidi G. et al. The mechanism of action of BCG therapy for bladder cancer – a current perspective // Nat. Rev. Urol. -2014. -№ 11. – с. 153 82. Weichselbaum R. R. et al. Radiotherapy and immunotherapy: a beneficial liaison? // Nat. Rev. Clin. Oncol. -2017. -№ 14. – с. 365 83. Kroemer G. et al. Immunogenic cell death in cancer therapy // Annu. Rev. Immunol. -2013. -№ 31. – с. 51 84. Apetoh L. et al. Toll- like receptor 4dependent contribution of the immune system to anticancer chemotherapy and radiotherapy // Nat. Med. -2007. -№ 13. – с. 1050 85. Twyman-Saint Victor C. et al. Radiation and dual checkpoint blockade activate non- redundant immune mechanisms in cancer // Nature -2015. -№ 520. – с. 373 86. Seifert L. et al. Radiation therapy induces macrophages to suppress T- cell responses against pancreatic tumors in mice // Gastroenterology -2016. - № 150. – с. 1659 87. Patel S. A. et al. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies // Immunity -2018. -№ 48. – с. 417 88. Goldsmith K. et al. Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response // J. Exp. Med. 1998. -№ 187. – с. 341 89. Ribas A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy // Cell -2018. -№ 174. – с. 1031 90. Ribas A. et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study // Cancer Discov. -2018. - № 8. – с. 1250 91. Guiducci C. et al. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection // Cancer Res. -2005. -№ 65. – с. 3437 92. Vicari A. P. et al. Reversal of tumor- induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody // J. Exp. Med. -2002. -№ 196. – с. 541 93. Sagiv-Barfi I. et al. Eradication of spontaneous malignancy by local immunotherapy // Sci. Transl. Med. -2018. -№ 10. – с. eaan4488 94. Ishizuka J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade // Nature -2018. -№ 565. – с. 43 95. Wang H. et al. cGAS is essential for the antitumor effect of immune checkpoint blockade // Proc. Natl Acad. Sci. USA -2017. -№ 114. – с. 1637 96. Morrison A. H. et al. Immunotherapy and prevention of pancreatic cancer // Trends cancer -2018. -№ 4. – с. 418 97. Byrne K. T. et al. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer // Cell Rep. -2016. -№ 15. – с. 2719 98. Ma D. Y. et al. The role of CD40 and CD154/CD40L in dendritic cells // Semin. Immunol. - 2009. -№ 21. – с. 265 99. Roybal K. T. et al. Synthetic immunology: hacking immune cells to expand their therapeutic capabilities // Annu. Rev. Immunol. -2017. -№ 35. – с. 229 100. Ljunggren H. G. et al. In search of the «missing self»: MHC molecules and NK cell recognition // Immunol. Today -1990. -№ 11. – с. 237 101. Andre P. et al. Anti- NKG2A mAb is a checkpoint inhibitor that promotes anti- tumor immunity by unleashing both T and NK cells // Cell - 2018. -№ 175. – с. 1731